This study strongly indicates that the combination of hERG1 positivity and Glut-1 negativity behaves as a prognostic biomarker in radically resected CRC patients. This combination identifies a group of stage I and II CRC patients with a bad prognosis, even worse than that of stage III patients, regardless of adjuvant therapy accomplishment.
HERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy / Muratori, Leonardo; Petroni, Giulia; Antonuzzo, Lorenzo; Boni, Luca; Iorio, Jessica; Lastraioli, Elena; Bartoli, Gianluca; Messerini, Luca; Di Costanzo, Francesco; Arcangeli, Annarosa. - In: ONCOTARGETS AND THERAPY. - ISSN 1178-6930. - ELETTRONICO. - 9:(2016), pp. 6325-6332. [10.2147/OTT.S114090]
HERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy
muratori, leonardo;PETRONI, GIULIA;ANTONUZZO, LORENZO;BONI, LUCA;IORIO, JESSICA;LASTRAIOLI, ELENA;BARTOLI, GIANLUCA;MESSERINI, LUCA;DI COSTANZO, FRANCESCO;ARCANGELI, ANNAROSA
2016
Abstract
This study strongly indicates that the combination of hERG1 positivity and Glut-1 negativity behaves as a prognostic biomarker in radically resected CRC patients. This combination identifies a group of stage I and II CRC patients with a bad prognosis, even worse than that of stage III patients, regardless of adjuvant therapy accomplishment.
| File | Dimensione | Formato | |
|---|---|---|---|
|
ott-9-6325.pdf
accesso aperto
Descrizione: Articolo principale
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
1.27 MB
Formato
Adobe PDF
|
1.27 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
